Inactive Instrument

Other languages Tekmira Pharmaceuticals Corporation Toronto S.E.

Equities

TKM

CA87911B2093

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial	Jun. 06
Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial	Jun. 06
Arbutus Biopharma Corporation Announces New Data from its Phase 2a Clinical Trial IM-PROVE I (AB-729-201)	Jun. 05
Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma	May. 20
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17
Sector Update: Health Care Stocks Softer Friday Afternoon	May. 17
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders	May. 17
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner	May. 17
Whitefort Capital Management Engages with Arbutus Biopharma	May. 09
Arbutus Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024	May. 02
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	Apr. 05
Moderna Suffers Setback in Lawsuit by Arbutus	Apr. 04
Moderna shares fall after judge sides with Arbutus in patent fight	Apr. 03
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	Jan. 08
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	Nov. 09
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut	Nov. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tekmira Pharmaceuticals Corporation Toronto S.E.

Equities

TKM

CA87911B2093

Other languages

Filters